Nadim M Rayess, MD
Ophthalmology · Tampa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Retina Associates of Florida, P.A. · 3 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rayess’s office at (813) 875-6373 to ask if they take your plan before you enroll.
California Medical Board record
Licence A151249 · Cancelled
Licence status: Cancelled · since 2017 · American University of Beirut Faculty of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$1,376,294
Medicare paid this office $1,376,294 for 513 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 166 | $941,148 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 15 | $101,213 | None |
| Injection of drug into eye | 243 | $65,484 | $94 |
| Injection, aflibercept, 1 mg | 25 | $65,277 | None |
| Established patient complete exam of visual system | 246 | $43,031 | $81 |
See all 15 services
| Injection, faricimab-svoa, 0.1 mg | 166 | $941,148 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 15 | $101,213 | None |
| Injection of drug into eye | 243 | $65,484 | $94 |
| Injection, aflibercept, 1 mg | 25 | $65,277 | None |
| Established patient complete exam of visual system | 246 | $43,031 | $81 |
| Injection, ranibizumab, 0.1 mg | 27 | $40,272 | None |
| Imaging of retina | 452 | $26,351 | $28 |
| Return visit (30+ min) | 166 | $21,033 | $90 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 16 | $20,572 | $190 |
| New patient visit (45+ min) | 95 | $10,191 | $107 |
| 1d and 2d ultrasound scan of eye tissue and structures | 17 | $1,396 | $44 |
| Short return visit (20+ min) | 14 | $1,202 | $71 |
| Unclassified drugs | 11 | $1,133 | None |
| Photography of the retina | 21 | $766 | $23 |
| Extended exam of the back part of the eye with retinal drawing | 18 | $287 | $14 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
513 Original Medicare patients in 2024. Average age 78 · Under 65 2% · 85 and older 25% · Women 59% · Also on Medicaid 2% · Health risk score 1.53. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Chronic kidney disease 34% · Coronary heart disease 32% · Diabetes 29% · Atrial fibrillation 22% · Depression 22% · Heart failure 19% · COPD 19% · Cancer 16% · Stroke 12% · Dementia 8%.
The office billed $3,642,525, Medicare allowed $1,759,665 and paid $1,376,294; for 38,518 services of 39 kinds; $1,185,212 of it was for drugs given in the office and $191,082 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 513 | 38,518 | 78 | 1.53 | $3,642,525 | $1,376,294 |
| 2023 | 530 | 28,449 | 78 | 1.60 | $3,462,190 | $1,235,109 |
| 2022 | 491 | 10,130 | 79 | 1.63 | $3,719,086 | $1,255,044 |
| 2021 | 281 | 1,760 | 79 | 1.61 | $1,220,571 | $410,320 |
| 2020 | 114 | 147 | 75 | 1.64 | $135,263 | $8,619 |
| 2019 | 71 | 86 | 73 | 1.34 | $135,814 | $6,929 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Injection, faricimab-svoa, 0.1 mg | 131 | $709,083 | None |
| Injection, ranibizumab, 0.1 mg | 68 | $195,107 | None |
| Injection, aflibercept, 1 mg | 36 | $105,100 | None |
| Injection of drug into eye | 244 | $65,071 | $97 |
| Established patient complete exam of visual system | 220 | $40,801 | $88 |
| Imaging of retina | 444 | $24,668 | $30 |
| Return visit (30+ min) | 140 | $18,642 | $93 |
| New patient visit (45+ min) | 151 | $17,548 | $116 |
| Unclassified drugs | 11 | $3,035 | None |
| 1d and 2d ultrasound scan of eye tissue and structures | 18 | $1,663 | $45 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 13 | $1,508 | $101 |
| Compounded drug, not otherwise classified | 13 | $1,000 | None |
| Short return visit (20+ min) | 12 | $977 | $70 |
| Photography of the retina | 20 | $691 | $26 |
| Extended exam of the back part of the eye with retinal drawing | 36 | $641 | $17 |
2022: 13 services
| Injection, ranibizumab, 0.1 mg | 167 | $508,330 | None |
| Injection, aflibercept, 1 mg | 62 | $233,282 | None |
| Unclassified drugs | 74 | $178,359 | None |
| Injection, faricimab-svoa, 0.1 mg | 57 | $155,772 | None |
| Injection of drug into eye | 261 | $72,813 | $99 |
| Established patient complete exam of visual system | 167 | $22,687 | $89 |
| Return visit (30+ min) | 136 | $17,586 | $93 |
| Imaging of retina | 376 | $17,392 | $29 |
| New patient visit (45+ min) | 155 | $16,512 | $107 |
| Compounded drug, not otherwise classified | 11 | $3,053 | None |
| Short return visit (20+ min) | 16 | $1,305 | $69 |
| Extended exam of the back part of the eye with retinal drawing | 34 | $649 | $17 |
| Photography of the retina | 20 | $641 | $25 |
2021: 8 services
| Injection, ranibizumab, 0.1 mg | 120 | $249,384 | None |
| Injection, aflibercept, 1 mg | 40 | $102,427 | None |
| Injection of drug into eye | 169 | $23,726 | $103 |
| New patient visit (45+ min) | 52 | $7,044 | $135 |
| Return visit (30+ min) | 66 | $6,609 | $100 |
| Imaging of retina | 125 | $4,534 | $32 |
| Established patient complete exam of visual system | 24 | $2,430 | $97 |
| Short return visit (20+ min) | 35 | $2,345 | $56 |
2020: 3 services
| Short return visit (20+ min) | 54 | $2,099 | $39 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 20 | $1,078 | $41 |
| Imaging of retina | 22 | $514 | $22 |
2019: 2 services
| Removal of eye fluid (vitreous) between lens and retina | 11 | $1,657 | $138 |
| Short return visit (20+ min) | 25 | $1,190 | $46 |
Drugs they prescribed that Part D paid
$15,795
Pharmacies billed $15,795 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 263) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
145 generic and 118 brand-name prescriptions · $15,795 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 74 | $3,146 | $43 |
| Eplerenone | 14 | $848 | $61 |
| Moxifloxacin | 30 | $783 | $26 |
| Ketorolac Tromethamine | 17 | $367 | $22 |
| Dorzolamide | 14 | $243 | $17 |
See all 8 drugs
| Prednisolone Acetate | 74 | $3,146 | $43 |
| Eplerenone | 14 | $848 | $61 |
| Moxifloxacin | 30 | $783 | $26 |
| Ketorolac Tromethamine | 17 | $367 | $22 |
| Dorzolamide | 14 | $243 | $17 |
| Dorzolamide-Timolol | 13 | $230 | $18 |
| Latanoprost | 34 | $191 | $6 |
| Timolol Maleate | 12 | $177 | $15 |
Year by year
| 2024 | 263 | 70 | 0% (0) | 45% | $15,795 |
| 2023 | 194 | 65 | None | 41% | $19,046 |
| 2022 | 126 | 44 | 0% (0) | 45% | $9,604 |
| 2021 | 151 | 47 | 0% (0) | 42% | $10,300 |
| 2020 | 133 | 65 | None | 44% | $182,570 |
| 2019 | 366 | 73 | 0% (0) | 37% | $194,682 |
| 2018 | 209 | 34 | None | 31% | $16,733 |
| 2017 | 23 | None | 0% (0) | 52% | $2,445 |
| 2016 | 158 | 34 | None | None | $11,343 |
| 2015 | 36 | None | 0% (0) | 33% | $3,360 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Prolensa | 16 | $6,185 | $387 |
| Prednisolone Acetate | 48 | $2,882 | $60 |
| Moxifloxacin | 32 | $1,202 | $38 |
| Dorzolamide | 11 | $404 | $37 |
| Dorzolamide-Timolol | 11 | $375 | $34 |
| Latanoprost | 18 | $183 | $10 |
| Prednisone | 11 | $81 | $7 |
2022: 3 drugs
| Prednisolone Acetate | 24 | $1,575 | $66 |
| Moxifloxacin | 18 | $766 | $43 |
| Latanoprost | 17 | $309 | $18 |
2021: 4 drugs
| Prednisolone Acetate | 29 | $1,978 | $68 |
| Brimonidine | 13 | $908 | $70 |
| Latanoprost | 36 | $831 | $23 |
| Dorzolamide | 13 | $727 | $56 |
2020: 3 drugs
| Latanoprost | 28 | $683 | $24 |
| Prednisolone Acetate | 17 | $650 | $38 |
| Prednisone | 12 | $194 | $16 |
2019: 7 drugs
| Brimonidine | 52 | $15,389 | $296 |
| Alphagan P | 15 | $3,159 | $211 |
| Dorzolamide-Timolol | 77 | $1,977 | $26 |
| Prednisolone Acetate | 34 | $1,316 | $39 |
| Latanoprost | 85 | $1,037 | $12 |
| Ketorolac Tromethamine | 19 | $410 | $22 |
| Ofloxacin | 17 | $256 | $15 |
2018: 6 drugs
| Brimonidine | 26 | $9,888 | $380 |
| Prednisolone Acetate | 17 | $800 | $47 |
| Dorzolamide-Timolol | 46 | $662 | $14 |
| Latanoprost | 61 | $596 | $10 |
| Ketorolac Tromethamine | 15 | $255 | $17 |
| Ofloxacin | 16 | $251 | $16 |
2016: 1 drug
| Simvastatin | 14 | $60 | $4 |
Money from drug and device companies
$2,387 in 2025
| 2025 | 12 | 38 | $189 | $2,387 |
| 2024 | 11 | 49 | $5,027 | $8,119 |
| 2023 | 12 | 45 | None | $2,992 |
| 2022 | 11 | 45 | None | $2,767 |
| 2021 | 7 | 14 | None | $1,084 |
| 2020 | 2 | 2 | $350 | $473 |
| 2019 | 7 | 18 | None | $2,502 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Vabysmo | $841 | 12 payments
|
| Apellis Pharmaceuticals | Syfovre | $571 | 10 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $188 | 4 payments
|
| Amgen | Tepezza | $150 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea Hd | $143 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $140 | 1 payment
|
See all 38 published payments
| Bausch & Lomb Americas | Meals · 2025-12-19 | Xipere | $22 |
| Apellis Pharmaceuticals | Consulting · 2025-12-10 | Syfovre | $189 |
| Genentech USA | Meals · 2025-12-03 | Vabysmo | $29 |
| Apellis Pharmaceuticals | Meals · 2025-12-03 | Syfovre | $31 |
| Genentech USA | Meals · 2025-12-02 | Susvimo | $128 |
| ANI Pharmaceuticals | Meals · 2025-11-19 | Iluvien | $29 |
| Genentech USA | Meals · 2025-11-17 | Vabysmo | $26 |
| Genentech USA | Meals · 2025-11-12 | Vabysmo | $138 |
| Astellas Pharma US | Meals · 2025-11-05 | Izervay | $23 |
| Apellis Pharmaceuticals | Meals · 2025-10-29 | Syfovre | $31 |
| Harrow Eye | Meals · 2025-10-19 | Triesence | $50 |
| Apellis Pharmaceuticals | Meals · 2025-10-15 | Syfovre | $76 |
| Apellis Pharmaceuticals | Meals · 2025-09-18 | Syfovre | $122 |
| Apellis Pharmaceuticals | Meals · 2025-09-10 | Syfovre | $35 |
| Genentech USA | Meals · 2025-08-27 | Vabysmo | $18 |
| Astellas Pharma US | Meals · 2025-08-27 | Izervay | $24 |
| Apellis Pharmaceuticals | Meals · 2025-08-21 | Syfovre | $23 |
| Genentech USA | Meals · 2025-08-18 | Vabysmo | $27 |
| Apellis Pharmaceuticals | Meals · 2025-06-19 | Syfovre | $21 |
| Genentech USA | Meals · 2025-06-18 | Vabysmo | $114 |
| Abbvie | Meals · 2025-06-11 | Ozurdex | $33 |
| Regeneron Healthcare Solutions | Meals · 2025-05-28 | Eylea Hd | $26 |
| Genentech USA | Meals · 2025-05-22 | Susvimo | $142 |
| Regeneron Healthcare Solutions | Meals · 2025-04-23 | Eylea Hd | $26 |
| Apellis Pharmaceuticals | Meals · 2025-04-17 | Syfovre | $26 |
| Apellis Pharmaceuticals | Meals · 2025-04-16 | Syfovre | $18 |
| Bausch & Lomb Americas | Meals · 2025-04-10 | Xipere | $32 |
| Genentech USA | Meals · 2025-04-09 | Vabysmo | $130 |
| Regeneron Healthcare Solutions | Meals · 2025-04-09 | Eylea Hd | $22 |
| Genentech USA | Meals · 2025-04-02 | Vabysmo | $25 |
| Genentech USA | Meals · 2025-03-19 | Vabysmo | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-02-28 | Eylea Hd | $114 |
| Genentech USA | Meals · 2025-02-27 | Vabysmo | $34 |
| ANI Pharmaceuticals | Meals · 2025-02-12 | Yutiq | $25 |
| Alcon Vision | Meals · 2025-02-01 | Constellation | $115 |
| Regeneron Pharmaceuticals | Meals · 2025-01-29 | Eylea Hd | $143 |
| Tarsus Pharmaceuticals | Meals · 2025-01-23 | Xdemvy | $140 |
| Amgen | Meals · 2025-01-09 | Tepezza | $150 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $8,119
| Regeneron Pharmaceuticals | Eylea Hd | $3,653 | 6 payments
|
| Apellis Pharmaceuticals | Syfovre | $2,388 | 10 payments
|
| Genentech USA | Vabysmo | $768 | 12 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $348 | 6 payments
|
| Harrow Eye | Iheezo | $321 | 2 payments
|
| Alimera Sciences | Yutiq | $227 | 3 payments
|
| Dompe US | Oxervate | $122 | 1 payment
|
| Sandoz | Cimerli | $112 | 4 payments
|
| Coherus Biosciences | Cimerli | $94 | 2 payments
|
| Alcon Vision | Constellation | $46 | 1 payment
|
| Ocular Therapeutix | Dextenza | $40 | 2 payments
|
2023: $2,992
| Genentech USA | Vabysmo | $619 | 11 payments
|
| Regeneron Pharmaceuticals | Eylea | $496 | 5 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $463 | 7 payments
|
| Apellis Pharmaceuticals | Syfovre | $304 | 4 payments
|
| Alimera Sciences | Iluvien | $276 | 4 payments
|
| Astellas Pharma US | Izervay | $207 | 4 payments
|
| Alcon Vision | Constellation | $157 | 2 payments
|
| Ocular Therapeutix | Dextenza | $126 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $125 | 1 payment
|
| Biogen | None | $99 | 1 payment
|
| Coherus Biosciences | Cimerli | $89 | 4 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $31 | 1 payment
|
2022: $2,767
| Genentech USA | Lucentis | $889 | 16 payments
|
| Regeneron Healthcare Solutions | Eylea | $478 | 9 payments
|
| Alimera Sciences | Iluvien | $271 | 7 payments
|
| Regeneron Pharmaceuticals | Eylea | $240 | 4 payments
|
| Bausch & Lomb Americas | Xipere | $157 | 3 payments
|
| Apellis Pharmaceuticals | None | $125 | 1 payment
|
| EyePoint Pharmaceuticals US | Yutiq | $125 | 1 payment
|
| Immunocore | Kimmtrak | $125 | 1 payment
|
| Abbvie | Xen Glaucoma Treatment System | $124 | 1 payment
|
| Sight Sciences | Omni(R) Surgical System (US) | $120 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $113 | 1 payment
|
2021: $1,084
| Allergan | Durysta | $327 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $240 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $205 | 2 payments
|
| Genentech USA | Susvimo | $177 | 3 payments
|
| Alimera Sciences | Iluvien | $101 | 2 payments
|
| Novartis Pharmaceuticals | Beovu | $17 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Xipere | $17 | 1 payment
|
2020: $473
| Alimera Sciences | Iluvien | $350 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $123 | 1 payment
|
2019: $2,502
| Alcon Vision | Acrysof | $1,612 | 10 payments
|
| Alimera Sciences | Iluvien | $250 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Envista | $250 | 2 payments
|
| Novartis Pharmaceuticals | None | $125 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $117 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis 1-Piece Iol | $98 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $51 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 95.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1144615212
- Licence
- CA A151249California A151249: Cancelled
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Student in a training program (390200000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-04-05
- NPI last updated
- 2019-05-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4201 Saint Antoine St # 9c, Detroit, MI, 48201